OBJECTIVE: The aim of this study was to evaluate and validate the proposed 8th edition American Joint Committee on Cancer (AJCC) system for T and N staging of pancreatic adenocarcinoma. SUMMARY OF BACKGROUND DATA: Investigators have questioned the clinical relevance and reproducibility of previous AJCC staging for pancreatic adenocarcinoma. METHODS: Prospective databases at Memorial Sloan Kettering (MSK), Massachusetts General Hospital (MGH), and Johns Hopkins Hospital (JHH) were queried for patients who had undergone resection for pancreatic adenocarcinoma. Patients who underwent a margin-negative (R0) resection, and who had previously undergone pathologic review, were included. Patients were staged according to 7th edition AJCC criteria, as well as the proposed 8th edition system that includes different definitions of tumor size (T) and nodal status (N). The dataset was randomly split into training and test sets. RESULTS: Two thousand three hundred eighteen patients were identified who met inclusion criteria. Recursive partitioning on the training set (n = 1551) identified statistically appropriate cutoffs for tumor size (<2.2 cm, ≥4.8 cm,) and nodal status (no positive nodes, 1 to 3 positive nodes, ≥4 positive nodes) that supported the proposed 8th edition changes. Median survival in patients staged as T3, N0 by the 7th edition definitions was different between institutions (median Center 1, 24 mo; Center 2, 37 mo; Center 3, 29 mo; P = 0.054). This difference was not observed when patients were staged as T3, N0 by 8th edition criteria. Stage, and stage-specific outcome (7th edition), on the test set revealed a predominance of patients (68%) within the IIB subgroup, and a concordance probability estimate (CPE) of 0.57 for stage-specific survival. When assessed with 8th edition criteria, no stage subgroup had a majority of patients, and the CPE was 0.58. CONCLUSIONS: The proposed 8th edition changes for T and N classification were statistically valid and may allow a more reproducible system of T staging. This system also stratifies patients more evenly across stages without sacrificing prognostic accuracy.
OBJECTIVE: The aim of this study was to evaluate and validate the proposed 8th edition American Joint Committee on Cancer (AJCC) system for T and N staging of pancreatic adenocarcinoma. SUMMARY OF BACKGROUND DATA: Investigators have questioned the clinical relevance and reproducibility of previous AJCC staging for pancreatic adenocarcinoma. METHODS: Prospective databases at Memorial Sloan Kettering (MSK), Massachusetts General Hospital (MGH), and Johns Hopkins Hospital (JHH) were queried for patients who had undergone resection for pancreatic adenocarcinoma. Patients who underwent a margin-negative (R0) resection, and who had previously undergone pathologic review, were included. Patients were staged according to 7th edition AJCC criteria, as well as the proposed 8th edition system that includes different definitions of tumor size (T) and nodal status (N). The dataset was randomly split into training and test sets. RESULTS: Two thousand three hundred eighteen patients were identified who met inclusion criteria. Recursive partitioning on the training set (n = 1551) identified statistically appropriate cutoffs for tumor size (<2.2 cm, ≥4.8 cm,) and nodal status (no positive nodes, 1 to 3 positive nodes, ≥4 positive nodes) that supported the proposed 8th edition changes. Median survival in patients staged as T3, N0 by the 7th edition definitions was different between institutions (median Center 1, 24 mo; Center 2, 37 mo; Center 3, 29 mo; P = 0.054). This difference was not observed when patients were staged as T3, N0 by 8th edition criteria. Stage, and stage-specific outcome (7th edition), on the test set revealed a predominance of patients (68%) within the IIB subgroup, and a concordance probability estimate (CPE) of 0.57 for stage-specific survival. When assessed with 8th edition criteria, no stage subgroup had a majority of patients, and the CPE was 0.58. CONCLUSIONS: The proposed 8th edition changes for T and N classification were statistically valid and may allow a more reproducible system of T staging. This system also stratifies patients more evenly across stages without sacrificing prognostic accuracy.
Authors: Jordan M Winter; Murray F Brennan; Laura H Tang; Michael I D'Angelica; Ronald P Dematteo; Yuman Fong; David S Klimstra; William R Jarnagin; Peter J Allen Journal: Ann Surg Oncol Date: 2011-07-15 Impact factor: 5.344
Authors: Jordan M Winter; Wei Jiang; Olca Basturk; Mari Mino-Kenudson; Zhi Ven Fong; Wei Phin Tan; Harish Lavu; Charles M Vollmer; Emma E Furth; Dana Haviland; David S Klimstra; William R Jarnagin; Keith D Lillemoe; Charles J Yeo; Carlos Fernandez-Del Castillo; Peter J Allen Journal: Ann Surg Date: 2016-04 Impact factor: 12.969
Authors: Nadia K Malik; Kilian Salerno May; Rameela Chandrasekhar; Wen Wee; Leayn Flaherty; Renuka Iyer; John Gibbs; Boris Kuvshinoff; Gregory Wilding; Graham Warren; Gary Y Yang Journal: J Gastrointest Oncol Date: 2012-12
Authors: Olca Basturk; Burcu Saka; Serdar Balci; Lauren M Postlewait; Jessica Knight; Michael Goodman; David Kooby; Juan M Sarmiento; Bassel El-Rayes; Hyejeong Choi; Pelin Bagci; Alyssa Krasinskas; Brian Quigley; Michelle D Reid; Gizem Akkas; Shishir K Maithel; Volkan Adsay Journal: Ann Surg Oncol Date: 2015-09-11 Impact factor: 5.344
Authors: Oliver Strobel; Ulf Hinz; Alexander Gluth; Thomas Hank; Thilo Hackert; Frank Bergmann; Jens Werner; Markus W Büchler Journal: Ann Surg Date: 2015-05 Impact factor: 12.969
Authors: Ding Ding; Ammar A Javed; Chunhui Yuan; Michael J Wright; Zunaira N Javed; Jonathan A Teinor; I Chae Ye; Richard A Burkhart; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He Journal: J Gastrointest Surg Date: 2020-02-05 Impact factor: 3.452
Authors: Zishuo I Hu; Jinru Shia; Zsofia K Stadler; Anna M Varghese; Marinela Capanu; Erin Salo-Mullen; Maeve A Lowery; Luis A Diaz; Diana Mandelker; Kenneth H Yu; Alice Zervoudakis; David P Kelsen; Christine A Iacobuzio-Donahue; David S Klimstra; Leonard B Saltz; Ibrahim H Sahin; Eileen M O'Reilly Journal: Clin Cancer Res Date: 2018-01-24 Impact factor: 12.531
Authors: Stijn van Roessel; Gyulnara G Kasumova; Joanne Verheij; Robert M Najarian; Laura Maggino; Matteo de Pastena; Giuseppe Malleo; Giovanni Marchegiani; Roberto Salvia; Sing Chau Ng; Susanna W de Geus; Sanne Lof; Francesco Giovinazzo; Jacob L van Dam; Tara S Kent; Olivier R Busch; Casper H van Eijck; Bas Groot Koerkamp; Mohammed Abu Hilal; Claudio Bassi; Jennifer F Tseng; Marc G Besselink Journal: JAMA Surg Date: 2018-12-19 Impact factor: 14.766